Correlation Between Microsoft and Lixte Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Microsoft and Lixte Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Lixte Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and Lixte Biotechnology Holdings, you can compare the effects of market volatilities on Microsoft and Lixte Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Lixte Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Lixte Biotechnology.

Diversification Opportunities for Microsoft and Lixte Biotechnology

0.35
  Correlation Coefficient

Weak diversification

The 3 months correlation between Microsoft and Lixte is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Lixte Biotechnology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lixte Biotechnology and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Lixte Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lixte Biotechnology has no effect on the direction of Microsoft i.e., Microsoft and Lixte Biotechnology go up and down completely randomly.

Pair Corralation between Microsoft and Lixte Biotechnology

Given the investment horizon of 90 days Microsoft is expected to under-perform the Lixte Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Microsoft is 13.08 times less risky than Lixte Biotechnology. The stock trades about -0.14 of its potential returns per unit of risk. The Lixte Biotechnology Holdings is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  226.00  in Lixte Biotechnology Holdings on January 26, 2024 and sell it today you would earn a total of  102.00  from holding Lixte Biotechnology Holdings or generate 45.13% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Microsoft  vs.  Lixte Biotechnology Holdings

 Performance 
       Timeline  
Microsoft 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Lixte Biotechnology 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lixte Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point.

Microsoft and Lixte Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Microsoft and Lixte Biotechnology

The main advantage of trading using opposite Microsoft and Lixte Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Lixte Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lixte Biotechnology will offset losses from the drop in Lixte Biotechnology's long position.
The idea behind Microsoft and Lixte Biotechnology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities